CSIMarket
 


Adamas Pharmaceuticals Inc  (ADMS)
Other Ticker:  
 
 

ADMS's Revenue Growth by Quarter and Year

Adamas Pharmaceuticals Inc's Revenue results by quarter and year




ADMS Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter December - 13.32 0.57 0.04
III Quarter September - 10.61 - 0.14
II Quarter June - 7.57 - 0.22
I Quarter March 11.67 2.55 - 0.18
FY   11.67 34.05 0.57 0.58



ADMS Revenue first quarter 2019 Y/Y Growth Comment
Adamas Pharmaceuticals Inc achieved in the first quarter, above Company average Revenue surge of 357.45% year on year, to $ 11.67 millions.

Looking into first quarter results within Major Pharmaceutical Preparations industry 10 other companies have achieved higher Revenue growth. While Adamas Pharmaceuticals Inc' s Revenue doubling of 357.45% ranks overall at the positon no. 115 in the first quarter.




ADMS Revenue ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter December - 2236.84 % 1325 % -92.31 %
III Quarter September - - - -81.82 %
II Quarter June - - - -45 %
I Quarter March 357.45 % - - -21.74 %
FY   - 5873.68 % -1.72 % -

Financial Statements
Adamas Pharmaceuticals Inc's first quarter 2019 Revenue $ 11.67 millions ADMS's Income Statement
Adamas Pharmaceuticals Inc's first quarter 2018 Revenue $ 2.55 millions Quarterly ADMS's Income Statement
New: More ADMS's historic Revenue Growth >>


ADMS Revenue (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter December - 25.54 % - -71.43 %
III Quarter September - 40.16 % - -36.36 %
II Quarter June - 196.86 % - 22.22 %
I Quarter March -12.42 % 347.37 % - -65.38 %
FY (Year on Year)   - 5873.68 % -1.72 % -




Revenue first quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #11
Healthcare Sector #29
Overall #115

Revenue Y/Y Growth Statistics
High Average Low
26.76 % -22.97 % -93.95 %
(Mar 31 2019)   (Dec. 30, 2015)
Revenue first quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #11
Healthcare Sector #29
Overall #115
Revenue Y/Y Growth Statistics
High Average Low
26.76 % -22.97 % -93.95 %
(Mar 31 2019)   (Dec. 30, 2015)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Adamas Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
56700 % 4480.15 % -100 %
(Dec 31 2017)  


ADMS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2019 Adamas Pharmaceuticals Inc disclosed drop in Revenue sequentially by -12.42% to $ 11.67 millions, from $ 13.32 millions released a quarter before.

Some cyclical circumstance that commonly energize I. Quarter 2019 performance, have not rescue the I. Quarter for the Adamas Pharmaceuticals Inc, Saanvi Subramanium , Healthcare sector researcher said, she sees additional difficulties ahead for ADMS.

Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue quarter on quarter growth. While Adamas Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 2459.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #85
Healthcare Sector #295
Overall #2459
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #85
Healthcare Sector #295
Overall #2459
Revenue Q/Q Growth Statistics
High Average Low
56700 % 4480.15 % -100 %
(Dec 31 2017)  


ADMS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2019 Adamas Pharmaceuticals Inc disclosed drop in Revenue from the previous quarter by -12.42% to $ 11.67 millions, from $ 13.32 millions declared a quarter before.

Some periodic factors were not able to rescue the I. Quarter for the Adamas Pharmaceuticals Inc, Saanvi Subramanium , Healthcare sector researcher wrote, she cited certan pessimism for the Adamas Pharmaceuticals Inc's perspective and continued that average sequential Revenue growth is at 4480.15% for the Major Pharmaceutical Preparations's company.

Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue quarter on quarter growth. While Adamas Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 2459.


Adamas Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2019)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
12 Months Ending
(Jun 30 2017)
12 Months Ending
(Mar 31 2017)
Cumulative Revenue 12 Months Ending $ 43.16 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 1281.5 % - - - -
Year on Year Revenue Growth Overall Ranking # 20 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 26.76 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 115 # 60 # 25 # 3 # 2




Cumulative Revenue growth Comment
With 1281.5% annual Revenue growth, Adamas Pharmaceuticals Inc would report a record annual Revenue surge if the fiscal year would end on Mar 31 2019.

Among companies within the Healthcare sector 6 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 20.

Revenue TTM Q/Q Growth Statistics
High Average Low
26.76 %
-22.97 %
-93.95 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 11
Healthcare Sector # 7
Overall # 20

Revenue TTM Y/Y Growth Statistics
High Average Low
1281.5 %
109.4 %
-96.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 29
S&P 500 # 115
Cumulative Revenue growth Comment
With 1281.5% annual Revenue growth, Adamas Pharmaceuticals Inc would report a record annual Revenue surge if the fiscal year would end on Mar 31 2019.

Among companies within the Healthcare sector 6 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 20.

Revenue TTM Q/Q Growth Statistics
High Average Low
26.76 %
-22.97 %
-93.95 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 11
Healthcare Sector # 7
Overall # 20

Revenue TTM Y/Y Growth Statistics
High Average Low
1281.5 %
109.4 %
-96.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 29
S&P 500 # 115




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADMS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for ADMS's Competitors
Revenue Growth for Adamas Pharmaceuticals Inc's Suppliers
Revenue Growth for ADMS's Customers

You may also want to know
ADMS's Annual Growth Rates ADMS's Profitability Ratios ADMS's Asset Turnover Ratio ADMS's Dividend Growth
ADMS's Roe ADMS's Valuation Ratios ADMS's Financial Strength Ratios ADMS's Dividend Payout Ratio
ADMS's Roa ADMS's Inventory Turnover Ratio ADMS's Growth Rates ADMS's Dividend Comparisons



Companies with similar Revenue surge for the quarter ending Mar 31 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2019
Vitality Biopharma, Inc.  601.93 %$ 601.933 millions
Ibio, Inc.  575.64 %$ 575.641 millions
Denali Therapeutics Inc.  556.01 %$ 556.006 millions
Endonovo Therapeutics, Inc.  544.75 %$ 544.750 millions
Bellicum Pharmaceuticals, Inc.  501.30 %$ 501.299 millions
Siga Technologies Inc  498.37 %$ 498.368 millions
Pulse Biosciences, Inc.  492.86 %$ 492.857 millions
Medifirst Solutions, Inc.  480.22 %$ 480.220 millions
Hartman Vreit Xxi, Inc.  464.02 %$ 464.023 millions
Voyager Therapeutics, Inc.  451.70 %$ 451.699 millions
La Jolla Pharmaceutical Co  443.26 %$ 443.263 millions
Proteostasis Therapeutics, Inc.  430.79 %$ 430.786 millions
Mannkind Corp  403.55 %$ 403.550 millions
Flexion Therapeutics Inc  381.49 %$ 381.495 millions
Adamas Pharmaceuticals Inc  356.91 %$ 356.913 millions
Aclaris Therapeutics, Inc.  350.89 %$ 350.894 millions
Guided Therapeutics Inc  350.00 %$ 350.000 millions
Therapeutic Solutions International, Inc.  310.67 %$ 310.667 millions
Aytu Bioscience, Inc  291.42 %$ 291.423 millions
Plx Pharma Inc.  289.85 %$ 289.850 millions
Zogenix, Inc.  278.87 %$ 278.872 millions
Catasys, Inc.  256.41 %$ 256.410 millions
Portola Pharmaceuticals Inc  233.67 %$ 233.669 millions
Reshape Lifesciences Inc.  223.58 %$ 223.580 millions
Opiant Pharmaceuticals, Inc.  219.14 %$ 219.143 millions
Bionik Laboratories Corp.  203.85 %$ 203.848 millions
Mei Pharma, Inc.  188.45 %$ 188.453 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SHNL's Profile

Stock Price

SHNL's Financials

Business Description

Fundamentals

Charts & Quotes

SHNL's News

Suppliers

SHNL's Competitors

Customers & Markets

Economic Indicators

SHNL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2019 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071